Rezolute, Inc. announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in infants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results